DCK 抗体
(Deoxycytidine Kinase (DCK))
Deoxycytidine kinase (DCK) is required for the phosphorylation of several deoxyribonucleosides and their nucleoside analogs. Deficiency of DCK is associated with resistance to antiviral and anticancer chemotherapeutic agents. Conversely, increased deoxycytidine kinase activity is associated with increased activation of these compounds to cytotoxic nucleoside triphosphate derivatives. DCK is clinically important because of its relationship to drug resistance and sensitivity. [provided by RefSeq, Jul 2008].
| Catalog no. | 产品 | 适用 | 宿主 / 克隆类型 | 应用 | 价格和交货时间 |
|---|---|---|---|---|---|
| DCK 抗体 (AA 17-260) (Fluoro647) | 人 | 小鼠 Monoclonal |
|
|
|
| DCK 抗体 (C-Term) | 人 | 兔 Polyclonal |
|
|
|
| DCK 抗体 (AA 1-216) | 人 | 兔 Polyclonal |
|
|
|
| DCK 抗体 | 人 | 兔 Polyclonal |
|
|
|
| DCK 抗体 (AA 1-79) (FITC) | 人 | 兔 Polyclonal |
|
|
|
| DCK 抗体 (Alexa Fluor 680) | 人, 小鼠, 大鼠 | 兔 Polyclonal |
|
|
|
| DCK 抗体 (Alexa Fluor 555) | 人, 小鼠, 大鼠 | 兔 Polyclonal |
|
|
|
| DCK 抗体 (Alexa Fluor 647) | 人, 小鼠, 大鼠 | 兔 Polyclonal |
|
|
|
| DCK 抗体 (Alexa Fluor 750) | 人, 小鼠, 大鼠 | 兔 Polyclonal |
|
|
|
| DCK 抗体 (Alexa Fluor 488) | 人, 小鼠, 大鼠 | 兔 Polyclonal |
|
|
|
| DCK 抗体 (Alexa Fluor 594) | 人, 小鼠, 大鼠 | 兔 Polyclonal |
|
|
|
| DCK 抗体 (AA 1-260) | 人, 小鼠, 大鼠 | 兔 Polyclonal |
|
|
|
| DCK 抗体 | 小鼠 | 小鸡 Polyclonal |
|
|
|
| DCK 抗体 (FITC) | 小鼠 | 小鸡 Polyclonal |
|
|
|
| DCK 抗体 (Biotin) | 小鼠 | 小鸡 Polyclonal |
|
|
|
| DCK 抗体 (AA 17-260) | 人 | 小鼠 Monoclonal |
|
|
|
| DCK 抗体 (AA 62-112) | 人, 小鼠, 大鼠 | 兔 Polyclonal |
|
|
|
| DCK 抗体 (Biotin) | 人, 小鼠, 大鼠 | 兔 Polyclonal |
|
|
|
| DCK 抗体 (AA 171-200) | 人, 小鼠 | 兔 Polyclonal |
|
|
Primary Antibody
- WB (Western Blotting: 所列应用)
- IHC (Immunohistochemistry: 所列应用)
- IF (Immunofluorescence: 所列应用)
- FACS (Flow Cytometry: 所列应用)
- ICC (Immunocytochemistry: 所列应用)
- 适用
- 人
- 宿主
- 小鼠
- 克隆形成能力
- Monoclonal
- 克隆
- 3G10
- 标记
- Fluoro647
- 抗体亚型
- IgG2b
- 抗原表位
- AA 17-260
Primary Antibody
- WB (Western Blotting: 所列应用)
- ELISA (ELISA: 所列应用)
- IHC (Immunohistochemistry: 所列应用)
- IF (Immunofluorescence: 所列应用)
- IP (Immunoprecipitation: 所列应用)
- 适用
- 人
- 宿主
- 兔
- 克隆形成能力
- Polyclonal
- 标记
- unconjugated
- 抗体亚型
- IgG
- 抗原表位
- C-Term, AA 178-207
Primary Antibody
- WB (Western Blotting: 所列应用)
- IF (Immunofluorescence: 所列应用)
- 适用
- 人
- 宿主
- 兔
- 克隆形成能力
- Polyclonal
- 标记
- unconjugated
- 抗原表位
- AA 1-216
Primary Antibody
- ELISA (ELISA: 所列应用)
- 适用
- 人
- 宿主
- 兔
- 克隆形成能力
- Polyclonal
- 标记
- FITC
- 抗体亚型
- IgG
- 抗原表位
- AA 1-79
Primary Antibody
- WB (Western Blotting: 所列应用)
- ICC (Immunocytochemistry: 所列应用)
- IHC (p) (Immunohistochemistry (Paraffin-embedded Sections): 所列应用)
- 适用
- 人, 小鼠, 大鼠
- 宿主
- 兔
- 克隆形成能力
- Polyclonal
- 标记
- unconjugated
- 抗原表位
- AA 1-260
Primary Antibody
- WB (Western Blotting: 所列应用)
- ELISA (ELISA: 所列应用)
- IHC (Immunohistochemistry: 所列应用)
- IP (Immunoprecipitation: 所列应用)
- 适用
- 小鼠
- 宿主
- 小鸡
- 克隆形成能力
- Polyclonal
- 标记
- FITC
Primary Antibody
- WB (Western Blotting: 所列应用)
- ELISA (ELISA: 所列应用)
- IHC (Immunohistochemistry: 所列应用)
- IP (Immunoprecipitation: 所列应用)
- 适用
- 小鼠
- 宿主
- 小鸡
- 克隆形成能力
- Polyclonal
- 标记
- Biotin
Primary Antibody
- WB (Western Blotting: 所列应用)
- IF (Immunofluorescence: 所列应用)
- FACS (Flow Cytometry: 所列应用)
- IHC (p) (Immunohistochemistry (Paraffin-embedded Sections): 所列应用)
- 适用
- 人
- 宿主
- 小鼠
- 克隆形成能力
- Monoclonal
- 克隆
- 3G10
- 标记
- unconjugated
- 抗体亚型
- IgG2b
- 抗原表位
- AA 17-260
Primary Antibody
- WB (Western Blotting: 所列应用)
- 适用
- 人, 小鼠, 大鼠
- 宿主
- 兔
- 克隆形成能力
- Polyclonal
- 标记
- unconjugated
- 抗体亚型
- IgG
- 抗原表位
- AA 62-112
Primary Antibody
- WB (Western Blotting: 所列应用)
- IF (Immunofluorescence: 所列应用)
- IHC (p) (Immunohistochemistry (Paraffin-embedded Sections): 所列应用)
- 适用
- 人, 小鼠
- 宿主
- 兔
- 克隆形成能力
- Polyclonal
- 标记
- unconjugated
- 抗体亚型
- Ig Fraction
- 抗原表位
- AA 171-200
Latest Publications for our DCK 抗体
: "Bortezomib prevents cytarabine resistance in MCL, which is characterized by down-regulation of dCK and up-regulation of SPIB resulting in high NF-κB activity." in: BMC cancer, Vol. 18, Issue 1, pp. 466, (2018) (PubMed).
: "Prognostic effect of hENT1, dCK and HuR expression by morphological type in periampullary adenocarcinoma, including pancreatic cancer." in: Acta oncologica (Stockholm, Sweden), Vol. 55, Issue 3, pp. 286-96, (2016) (PubMed).
: "The effects of forodesine in murine and human multiple myeloma cells." in: Advances in hematology, Vol. 2010, pp. 131895, (2010) (PubMed).
: "Population-specific genetic variants important in susceptibility to cytarabine arabinoside cytotoxicity." in: Blood, Vol. 113, Issue 10, pp. 2145-53, (2009) (PubMed).
: "The role of HuR in gemcitabine efficacy in pancreatic cancer: HuR Up-regulates the expression of the gemcitabine metabolizing enzyme deoxycytidine kinase." in: Cancer research, Vol. 69, Issue 11, pp. 4567-72, (2009) (PubMed).
: "Laser microdissection and primary cell cultures improve pharmacogenetic analysis in pancreatic adenocarcinoma." in: Laboratory investigation; a journal of technical methods and pathology, Vol. 88, Issue 7, pp. 773-84, (2008) (PubMed).
: "Pharmacogenetics of deoxycytidine kinase: identification and characterization of novel genetic variants." in: The Journal of pharmacology and experimental therapeutics, Vol. 323, Issue 3, pp. 935-45, (2007) (PubMed).
: "Molecular basis of 2',3'-dideoxycytidine-induced drug resistance in human cells." in: Molecular and cellular biochemistry, Vol. 231, Issue 1-2, pp. 173-7, (2002) (PubMed).
: "Prognostic effect of hENT1, dCK and HuR expression by morphological type in periampullary adenocarcinoma, including pancreatic cancer." in: Acta oncologica (Stockholm, Sweden), Vol. 55, Issue 3, pp. 286-96, (2016) (PubMed).
: "The effects of forodesine in murine and human multiple myeloma cells." in: Advances in hematology, Vol. 2010, pp. 131895, (2010) (PubMed).
: "Population-specific genetic variants important in susceptibility to cytarabine arabinoside cytotoxicity." in: Blood, Vol. 113, Issue 10, pp. 2145-53, (2009) (PubMed).
: "The role of HuR in gemcitabine efficacy in pancreatic cancer: HuR Up-regulates the expression of the gemcitabine metabolizing enzyme deoxycytidine kinase." in: Cancer research, Vol. 69, Issue 11, pp. 4567-72, (2009) (PubMed).
: "Laser microdissection and primary cell cultures improve pharmacogenetic analysis in pancreatic adenocarcinoma." in: Laboratory investigation; a journal of technical methods and pathology, Vol. 88, Issue 7, pp. 773-84, (2008) (PubMed).
: "Pharmacogenetics of deoxycytidine kinase: identification and characterization of novel genetic variants." in: The Journal of pharmacology and experimental therapeutics, Vol. 323, Issue 3, pp. 935-45, (2007) (PubMed).
: "Molecular basis of 2',3'-dideoxycytidine-induced drug resistance in human cells." in: Molecular and cellular biochemistry, Vol. 231, Issue 1-2, pp. 173-7, (2002) (PubMed).
Aliases for DCK 抗体
deoxycytidine kinase (DCK) 抗体deoxycytidine kinase (dck) 抗体
deoxycytidine kinase, gene 2 L homeolog (dck.2.L) 抗体
deoxycytidine kinase, gene 2 (dck.2) 抗体
deoxycytidine kinase (Dck) 抗体
Deoxycytidine kinase (FPV059) 抗体
Deoxycytidine kinase (FPV151) 抗体
deoxycytidine kinase, gene 1 L homeolog (dck.1.L) 抗体
dck 抗体
DCK 抗体
dck1 抗体
wu:fc15f06 抗体
zgc:101771 抗体
您还需要查找其他产品吗？
You are here:
